Actinomycin D for Reinduction of Remission in Dogs With Resistant Lymphoma     

Anthony S. Moore BVSc  MVSc    Gregory K. Ogilvie  David M. Vail 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》1994,8(5):343-344

Twenty-five dogs with malignant lymphoma refractory to chemotherapy were treated with actinomycin D at a median dose of 0.7 mg/m² (range, 0.5 to 0.9 mg/m²) every 3 weeks. The dogs treated had received between 2 and 8 chemotherapeutic agents (median 7), for a median of 266 days before being treated with actinomycin D. For 23 of the 25 dogs, previous chemotherapy included doxorubicin. No dog responded to actinomycin D chemotherapy.  相似文献   

Response to Liposome-Encapsulated Doxorubicin (TLC D-99) in a Dog With Myeloma     

William C. Kisseberth  E. Gregory MacEwen  Stuart C. Helfand  David M. Vail  Cheryl L. London  Evan Keller 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》1995,9(6):425-428

  相似文献   

Conduct,Oversight, and Ethical Considerations of Clinical Trials in Companion Animals with Cancer: Report of a Workshop on Best Practice Recommendations          下载免费PDF全文

R. Page  P. Baneux  D. Vail  L. Duda  P. Olson  L. Anestidou  N. Dybdal  G. Golab  W. Shelton  M. Salgaller  C. Hardy 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2016,30(2):527-535

Development of effective and safe treatments for companion animals with cancer requires the collaboration of numerous animal health professionals and the full engagement of animal owners. Establishing ‘Best Practice Recommendations’ for clinical trials in veterinary oncology represents an important step toward meeting the goal of rigorous clinical trial design and conduct that is required to establish valid evidence. Likewise, optimizing patient welfare and owner education and advocacy is crucial to meet the unique ethical obligations to both owners and animals enrolled in these clinical trials and to ensure trust in the team conducting the research. To date, ‘Best Practice Recommendations’ for clinical trial conduct have not been reported for veterinary oncology. This document summarizes the consensus of a workshop held in November, 2014 to identify relevant ethical principles and to ensure responsible conduct of clinical research in companion animals with cancer. It is intended as a working document that will be updated as advances in science and ethical considerations require. To the extent possible, existing guidelines for the conduct and oversight of clinical trials in humans have been adapted for veterinary trials to avoid duplicative effort and to facilitate integration of clinical trials such that translational research with benefits for both companion animals and humans are encouraged.  相似文献   

Letter to Editor          下载免费PDF全文

Chand Khanna DVM  PhD  DACVIM  David Vail DVM  DACVIM  Mona Rosenberg DVM  DACVIM 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2016,30(1):9-9

  相似文献   

Irrigation of seed carrots on a sandy loam soil     

J. E. Ayars  R. B. Hutmacher  J. J. Steiner  A. B. Mantel  S. S. Vail 《Irrigation Science》1991,12(4):193-198

Summary Little research has been reported which quantifies the response of a carrot (Daucus carrota L. var sativa DC.) seed crop to water management. While the area of seed production of this crop in the United States is less than 3000ha, the return ranges from US $2000 to $ 10 000 ha^–1. Because of the need to mature and dry the seed on the plant, carrot seed is generally grown in areas with negligible summer rain and thus depends on irrigation to supply the crop water requirement. A study was conducted to determine the effect of irrigation water management on seed production and crop water use of carrots grown by the root-to-seed method. Two carrot types (Nantes and Imperator) were evaluated in 9 irrigation treatments over a three year study period. Irrigation treatments which replaced a percentage of the calculated crop evapotranspiration on either a daily basis or when a soil water depletion reached 30 mm were used. A trickle irrigation system with the laterals placed on the carrot bed was used to apply a uniform and accurate amount of water. There was a marked difference in the crop response to the water management of the two carrot types used. The Nantes type exhibited a positive response to moderate water deficits in terms of improved pure live seed (PLS) yield while the Imperator achieved its maximum yield when it was not stressed. Higher irrigation applications in the Nantes type resulted in reduced yields while the Imperator was not affected after its non-stress water requirement was met. Soil water data indicated that the most active zone of extraction of water was to a depth of 1.5 m in the soil profile. As the depth of applied water approached the crop water requirement, the depth of extraction was reduced. Increasing the frequency of irrigation also tended to reduce the depth of extraction of soil water. A total crop water use of approximately 550 to 620 mm was needed to achieve the best PLS yield which is roughly equal to potential evapotranspiration in the San Joaquin Valley, during the time that the crop water use was calculated. In such a climate, the irrigation interval should not exceed 3 to 5 days depending on the time of year.  相似文献   

Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986-1996)     

Hershey AE  Sorenmo KU  Hendrick MJ  Shofer FS  Vail DM 《Journal of the American Veterinary Medical Association》2000,216(1):58-61

OBJECTIVE: To evaluate time to first recurrence (TFR) and overall survival in cats with presumed vaccine-associated sarcomas (VAS) treated with excision. DESIGN: Retrospective study. ANIMALS: 61 cats with presumed VAS. PROCEDURE: Medical records of cats that received excision as the only initial treatment for presumed VAS were reviewed to evaluate prognosis. Overall survival curves and TFR were determined. RESULTS: Median TFR was 94 days. Median TFR for tumors treated with excision performed at a referral institution (274 days) was significantly longer than that for tumors excised by a referring veterinarian (66 days). Radical first excision yielded significantly longer median TFR (325 days) than did marginal first excision (79 days). Cats with tumors located on the limbs had longer median TFR (325 days) than cats with tumors located in other sites (66 days). Median overall survival time was 576 days. Significant differences in survival times between groups were not detected. Few cats (13.8%) receiving only surgical treatment had long-term (> 2 years) survival. CONCLUSIONS AND CLINICAL RELEVANCE: Radical first excision of presumed VAS is essential for extended TFR. Current recommendations for vaccination of the distal portions of the extremities are appropriate, because this practice permits radical excision of tumors (amputation) that develop at vaccination sites; however, surgery alone is seldom curative.  相似文献   

Cancer clinical trials: development and implementation.     

David M Vail 《Veterinary Clinics of North America: Small Animal Practice》2007,37(6):1033-57; v

Although much of the current standard of care in veterinary oncology is based on retrospective studies or transference from the human literature, a new era of clinical trial awareness brought on by new consortia and cooperative investigative groups is beginning to change this limitation. The use of controlled, randomized, blind multicenter trials testing new cytotoxics and cytostatic agents is now becoming the norm rather than the exception. Ultimately, advanced clinical trial design applied to companion animal populations should advance veterinary-based practice and inform future human clinical trials that may follow.  相似文献   

A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs          下载免费PDF全文

C. Khanna  M. Rosenberg  D. M. Vail 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2015,29(4):1006-1012

Paclitaxel is a commonly used chemotherapeutic agent with a broad spectrum of activity against cancers in humans. In 1992, paclitaxel was approved by the U.S. Food and Drug Administration (FDA) as Taxol^® for use in advanced ovarian cancer. Two years later, it was approved for the treatment of metastatic breast cancer. Paclitaxel was originally isolated from the bark of the Pacific yew tree, Taxus brevifolia in 1971. Taxanes are a family of microtubule inhibitors. As a member of this family, paclitaxel suppresses spindle microtubule dynamics. This activity results in the blockage of the metaphase‐anaphase transitions, and ultimately in the inhibition of mitosis, and induction of apoptosis in a wide spectrum of cancer cells. Additional anticancer activities of paclitaxel have been defined that are independent of these effects on the microtubules and may include the suppression of cell proliferation as well as antiangiogenic effects. Based on its targeting of a fundamental feature of the cancer phenotype, the mitotic complex, it is not surprising that paclitaxel has been found to be active in a wide variety of cancers in humans. This review summarizes the evidence in support of paclitaxel's broad anticancer activity and introduces the rationale for, and the progress in development of novel formulations of paclitaxel that may preferentially target cancers and that are not associated with the risks for hypersensitivity in dogs. Of note, a novel nanoparticle formulation of paclitaxel that substantially limits hypersensitivity was recently given conditional approval by the FDA Center for Veterinary Medicine for use in dogs with resectable and nonresectable squamous cell carcinoma and nonresectable stage III, IV and V mammary carcinoma.  相似文献   

Acanthocephalan infection and sparganosis in a green tree snake (Dendrelaphis punctulata)     

AG Hill  PW Ladds  DM Spratt 《Australian veterinary journal》2014,92(9):362-364

Acanthocephalan and spargana parasites were identified within a body wall mass during exploratory surgery in a wild green tree snake. Acanthocephalan parasites have not previously been reported in this species. Surgical excision, the treatment of choice, could not be achieved because of the extensive infiltration of the coelomic cavity.  相似文献   

Efficacy of mitoxantrone against various neoplasms in dogs   总被引：2，自引：0，他引：2  

G K Ogilvie  J E Obradovich  R E Elmslie  D M Vail  A S Moore  R C Straw  K Dickinson  M F Cooper  S J Withrow 《Journal of the American Veterinary Medical Association》1991,198(9):1618-1621

One hundred twenty-six dogs with histologically confirmed, measurable malignant tumors were evaluated in a prospective study to determine the response to the antineoplastic drug mitoxantrone. Ninety-five dogs had been refractory to one or more treatment modalities (surgery, n = 57; chemotherapy other than mitoxantrone, n = 37; radiation, n = 4; whole body hyperthermia, n = 1). The extent of neoplastic disease was determined immediately before each dose of mitoxantrone was administered (1 to 10 doses, 2.5 to 5 mg/m2 of body surface area, IV) 21 days apart. Each dog was treated with mitoxantrone until the dog developed progressive disease or until the dog's quality of life diminished to an unacceptable level as determined by the owner or attending veterinarian. A partial or complete remission (greater than 50% volume reduction) was obtained in 23% (29/126) of all dogs treated. Tumors in which there was a partial or complete remission included lymphoma (11/32), squamous cell carcinoma (4/9), fibrosarcoma (2/9), thyroid carcinoma (1/10), transitional cell carcinoma (1/6), mammary adenocarcinoma (1/6), hepatocellular carcinoma (1/4), renal adenocarcinoma (1/1), rectal carcinoma (1/1), chondrosarcoma (1/2), oral malignant melanoma (1/12), cutaneous malignant melanoma (1/1), myxosarcoma (1/1), mesothelioma (1/1), and hemangiopericytoma (1/1). Our results indicated that mitoxantrone induces measurable regression in various malignant tumors in dogs.  相似文献